Next Article in Journal
Comparison of Post-Remission Strategies in Acute Myeloid Leukemia: Autologous Hematopoietic Stem Cell Transplantation versus Consolidation Chemotherapy
Previous Article in Journal
Elucidating the Pivotal Role of Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: A Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 12
Issue 3
10.4081/hr.2020.8537
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Successful Long-Term Treatment with Azacitidine in Patient with Chronic Myelomonocytic Leukemia

by
Luka Čemažar
1,
Helena Podgornik
1,2,
Njetočka Gredelj Šimec
1 and
Samo Zver
1,3,*
1
Department of Hematology, University Clinical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia
2
Faculty of Pharmacy, University Clinical Centre Ljubljana, 1000 Ljubljana, Slovenia
3
Medical Faculty, University Clinical Centre Ljubljana, 1000 Ljubljana, Slovenia
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2020, 12(3), 8537; https://doi.org/10.4081/hr.2020.8537
Submission received: 12 March 2020 / Revised: 20 October 2020 / Accepted: 30 October 2020 / Published: 2 December 2020

Abstract

The purpose of this article was to present a case of successful long term treatment with azacitidine in patient with Chronic Myelomonocytic Leukemia (CMML) and discussing possible contributing factors for its long term efficacy. Data from our case were compared with similar data available in the literature. Effective treatment with azacitidine resulted in overall survival of 11 years 5 months and we showed that applying multiple cycles of treatment is feasible. Our patient received 71 cycles of treatment with total duration of 7 years and 3 months. Our report about a patient with CMML and a good clinical course revealed, that long term treatment with azacitidine is feasible in some patients. Initially low bone marrow blast count, a relatively small malignant CMML clone, reduction of spleen size and fast platelet response seemed to be factors determining long term response to treatment in our patient. More data on CMML treatment by Hypomethylating Agents and their analysis are needed in order to make firm conclusions.
Keywords: chronic myelomonocytic leukemia; azacitidine; long-term treatment chronic myelomonocytic leukemia; azacitidine; long-term treatment

Share and Cite

MDPI and ACS Style

Čemažar, L.; Podgornik, H.; Šimec, N.G.; Zver, S. Successful Long-Term Treatment with Azacitidine in Patient with Chronic Myelomonocytic Leukemia. Hematol. Rep. 2020, 12, 8537. https://doi.org/10.4081/hr.2020.8537

AMA Style

Čemažar L, Podgornik H, Šimec NG, Zver S. Successful Long-Term Treatment with Azacitidine in Patient with Chronic Myelomonocytic Leukemia. Hematology Reports. 2020; 12(3):8537. https://doi.org/10.4081/hr.2020.8537

Chicago/Turabian Style

Čemažar, Luka, Helena Podgornik, Njetočka Gredelj Šimec, and Samo Zver. 2020. "Successful Long-Term Treatment with Azacitidine in Patient with Chronic Myelomonocytic Leukemia" Hematology Reports 12, no. 3: 8537. https://doi.org/10.4081/hr.2020.8537

APA Style

Čemažar, L., Podgornik, H., Šimec, N. G., & Zver, S. (2020). Successful Long-Term Treatment with Azacitidine in Patient with Chronic Myelomonocytic Leukemia. Hematology Reports, 12(3), 8537. https://doi.org/10.4081/hr.2020.8537

Article Metrics

Back to TopTop